• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Zealand Pharma

321.20 DKK-5.86 %14.8, 16.59
Less than 1K followers

ZEAL

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-5.86 %
+14.35 %
+3.41 %
-19.64 %
-31.13 %
-5.83 %
+34.96 %
+88.72 %
+304.03 %

Zealand Pharma operates in biotechnology. Special focus is found in the development of drugs for the treatment of diabetes and various intestinal diseases. The company has a varied product portfolio with separate brands that are sold on a global level. The largest operations are in the Nordic market. Zealand Pharma was founded in 1997 and is headquartered in Søborg, Denmark.

Read more
Market cap
22.99B DKK
Turnover
189.02M DKK
Revenue
9.21B
EBIT %
75.52 %
P/E
3.51
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
12.11
2026

Interim report Q3'26

All
Research
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

HCA Morgenbørs 13/08 - BioMar CEO-interview og fokus danske regnskab
Video13.08.2026, 09.21 by
Michael Friis, Victor Skriver

HCA Morgenbørs 13/08 - BioMar CEO-interview og fokus danske regnskab

Udsigt til positiv åbning i Europa, drevet af en let aftagende inflation i USA onsdag. Herhjemme er der fokus på de regnskabsaktuelle Mærsk, Zealand Pharma, Pandora og Netcompany. Gæst i studiet her til morgen er BioMar's CEO, Carlos Diaz.

BioMar GroupD/S NordenZealand PharmaPandoraØrstedA.P. Møller - Mærsk
Analyst Comment13.08.2026, 07.19

HCA Red Flag: Zealand Pharma earns BDKK 3.9, but still burns cash (AI)

Expect a weak opening: the pre-tax profit of DKK 4,006 million DKK exceeded the expected MDKK 3,782. DKK alone, because Zealand Pharma spent MDKK 632 DKK vs. 789 MDKK DKK on petrelintide trials that have not yet started. Guidance was maintained, and a royalty sale adds approximately DKK 640M. DKK.

Zealand Pharma
Regulatory press release13.08.2026, 07.00

Zealand Pharma Announces Financial Results for the First Half of 2026

Zealand Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release12.08.2026, 22.05

Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide

Zealand Pharma
Regulatory press release10.08.2026, 17.00

Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)

Zealand Pharma
Regulatory press release03.08.2026, 17.00

Zealand Pharma - Transactions related to share buy-back program (week 31, 2026)

Zealand Pharma
Regulatory press release27.07.2026, 17.00

Zealand Pharma - Transactions related to share buy-back program (week 30, 2026)

Zealand Pharma
Regulatory press release20.07.2026, 22.00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Regulatory press release20.07.2026, 17.00

Zealand Pharma: Transactions related to share buy-back program (week 29, 2026)

Zealand Pharma
Regulatory press release13.07.2026, 17.00

Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)

Zealand Pharma
Regulatory press release06.07.2026, 17.00

Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)

Zealand Pharma
Regulatory press release30.06.2026, 22.01

Total number of shares and voting rights in Zealand Pharma as of June 30, 2026

Zealand Pharma
Regulatory press release30.06.2026, 22.00

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Zealand Pharma
Regulatory press release29.06.2026, 17.00

Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)

Zealand Pharma
Regulatory press release22.06.2026, 22.00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Regulatory press release22.06.2026, 17.00

Zealand Pharma - Transactions related to share buy-back program (week 25, 2026)

Zealand Pharma
HCA Morgenbørs 18/06 - Udsigt til divergerende markeder
Video18.06.2026, 09.36 by
Michael Friis, Rasmus Køjborg

HCA Morgenbørs 18/06 - Udsigt til divergerende markeder

Jyske BankH+H InternationalZealand PharmaBioMar GroupAGFLundbeck
HCA Morgenbørs 17/06 - FED rentemøde i fokus
Video17.06.2026, 09.20 by
Rasmus Køjborg, Victor Skriver

HCA Morgenbørs 17/06 - FED rentemøde i fokus

Udsigt til svagt faldende europæiske markeder her til morgen imens US futures peger den anden vej. Fokus herhjemme på bl.a. Novo Nordisk, Zealand Pharma og Maersk.

TormHafniaNovo NordiskZealand PharmaA.P. Møller - MærskScandinavian Medical SolutionsInstallatørGruppenFLSmidth & Co.BioMar GroupBar DjusNKT
HCA Morgenbørs 16/06 - Får vi nu også en åbning af Hormuz?
Video16.06.2026, 09.18 by
Michael Friis, Victor Skriver

HCA Morgenbørs 16/06 - Får vi nu også en åbning af Hormuz?

Flade futures globalt fra morgenstunden, Investorer diskuterer om vi nu også får en åbning af Hormuz fredag og afventede FED. herhjemme fokus på kursmålsændringer på en nyhedsfattig dag.

Novo NordiskZealand PharmaSolarDSVA.P. Møller - MærskAGF
Regulatory press release15.06.2026, 17.00

Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)

Zealand Pharma